Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00027300. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Study identification
- NCT ID
- NCT00027300
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 900 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2001 (Type not available)
- Primary completion
- Nov 2004 (Actual)
- Completion
- Jan 2005 (Actual)
- Last update posted
- Jan 9, 2017
2001 – 2005
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Scottsdale | Scottsdale | Arizona | 85259 | — |
| East Bay Region Associates in Neurology | Berkeley | California | 94705 | — |
| UC Davis School of Medicine, Department of Neurology | Davis | California | 95817-2307 | — |
| Yale University School of Medicine, Department of Neurology | New Haven | Connecticut | 06510 | — |
| University of Miami School of Medicine, Department of Neurology | Miami | Florida | 33136 | — |
| University of Kansas Medical Center, Department of Neurology | Kansas City | Kansas | 66160 | — |
| Michigan Institute for Neurological Disorders | Farmington Hills | Michigan | 48335 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Gimbel MS Center | Teaneck | New Jersey | 07666 | — |
| CMRRC | Albuquerque | New Mexico | 87131 | — |
| Oregon Health Sciences University, Department of Neurology | Portland | Oregon | 97201-3098 | — |
| Lehigh Valley Hospital, Neurosciences Research | Allentown | Pennsylvania | 18103 | — |
| Texas Neurology | Dallas | Texas | 75214 | — |
| University of Washington MS Research Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00027300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2017 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.